Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2112)	5/18/2004 4:34:42 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Millennium Pharmaceuticals "market perform" Tuesday, May 18, 2004 2:31:27 PM ET JMP Securities NEW YORK, May 18 (New Ratings) - Analysts at JMP Securities maintain their "market perform" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). In a research note published this morning, the analysts mention that Millennium Pharmaceuticals reported positive results from the Phase III APEX study of Velcade, the company's drug for the treatment of relapsed multiple myeloma (MM). The positive results would enable the company to expand its customer base, the analysts believe. However, JMP Securities believes that further catalysts are required to boost the company's share price in the near future.

To: Icebrg who wrote (2112)	5/25/2004 12:54:28 PM
From: tuck	Read Replies (1) \| Respond to of 3044

>>Cancer Cell. 2004 May;5(5):443-53. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D. Millenium Pharmaceuticals Inc., 75 Sidney Street, Cambridge, MA 02139 USA. Tumors develop through successive stages characterized by changes in gene expression and protein function. Gene expression profiling of pancreatic islet tumors in a mouse model of cancer revealed upregulation of cathepsin cysteine proteases. Cathepsin activity was assessed using chemical probes allowing biochemical and in vivo imaging, revealing increased activity associated with the angiogenic vasculature and invasive fronts of carcinomas, and differential expression in immune, endothelial, and cancer cells. A broad-spectrum cysteine cathepsin inhibitor was used to pharmacologically knock out cathepsin function at different stages of tumorigenesis, impairing angiogenic switching in progenitor lesions, as well as tumor growth, vascularity, and invasiveness. Cysteine cathepsins are also upregulated during HPV16-induced cervical carcinogenesis, further encouraging consideration of this protease family as a therapeutic target in human cancers.<< Wonder if there is any IP in this area, but don't have the time to look for a few weeks. Damn vacations, always interfering with research. Cheers, Tuck